Trial · NCT01372813
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 18 of 18
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Alkaline phosphatase | Investigations | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Bicarbonate, serum-low | Investigations | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Creatinine | Investigations | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Dry mouth/salivary gland (xerostomia) | Gastrointestinal disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Glucose, serum-high (hyperglycemia) | Metabolism and nutrition disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Hemoglobin | Blood and lymphatic system disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Hypertension | Vascular disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Magnesium, serum-high (hypermagnesemia) | Metabolism and nutrition disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Magnesium, serum-low (hypomagnesemia) | Metabolism and nutrition disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Nausea | Gastrointestinal disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 2 |
| other | Neurology - Other (Specify, lightheadedness) | Nervous system disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Pain::Neck | Musculoskeletal and connective tissue disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Phosphate, serum-low (hypophosphatemia) | Metabolism and nutrition disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Prolonged QTc interval | Investigations | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| other | Rash: acne/acneiform | Skin and subcutaneous tissue disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
| serious | Diarrhea | Gastrointestinal disorders | Clear Cell Renal Carcinoma Patients | 1 | 3 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01372813/events